Pfizer Inc. $PFE Shares Sold by Trivium Point Advisory LLC

Trivium Point Advisory LLC reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 53.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,408 shares of the biopharmaceutical company's stock after selling 51,899 shares during the quarter. Trivium Point Advisory LLC's holdings in Pfizer were worth $1,093,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of PFE. Gould Asset Management LLC CA lifted its position in shares of Pfizer by 16.5% during the second quarter. Gould Asset Management LLC CA now owns 9,062 shares of the biopharmaceutical company's stock worth $218,000 after purchasing an additional 1,283 shares in the last quarter. Global Retirement Partners LLC acquired a new position in shares of Pfizer in the second quarter valued at approximately $4,339,000. Bank of New York Mellon Corp grew its holdings in shares of Pfizer by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company's stock valued at $1,393,739,000 after purchasing an additional 3,999,646 shares in the last quarter. Prospect Financial Services LLC increased its stake in Pfizer by 48.6% during the 2nd quarter. Prospect Financial Services LLC now owns 10,711 shares of the biopharmaceutical company's stock worth $258,000 after buying an additional 3,505 shares during the period. Finally, Private Advisory Group LLC increased its stake in Pfizer by 13.3% during the 2nd quarter. Private Advisory Group LLC now owns 254,299 shares of the biopharmaceutical company's stock worth $6,124,000 after buying an additional 29,858 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Weiss Ratings cut shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday. Citigroup upped their price objective on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 29th. Guggenheim reduced their price objective on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. JPMorgan Chase & Co. decreased their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. Finally, Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $28.28.

Pfizer Stock Up 0.8%

Shares of NYSE:PFE opened at $28.00 on Friday. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The firm's 50 day moving average price is $25.30 and its 200 day moving average price is $26.25. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market cap of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The firm's revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's payout ratio is presently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source